All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Hans LeeDuring the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Hans Lee, MD Anderson Cancer Center, Houston, US. We asked: can belantamab mafodotin be used in patients with renal impairment?
In this video, Hans Lee describes the results of a post hoc analysis of the DREAMM-2 study, where patients with relapsed/refractory multiple myeloma who were treated with belantamab mafodotin were analyzed based on renal function. Patients were characterized into three groups (normal, mild, and moderate) based on the glomerular filtration rate. He also discusses the overall survival rates, duration of response, progression-free survival and safety profile including, analysis of keratopathy and albuminuria.
Can belantamab mafodotin be used in patients with renal impairment?
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?